Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
Status:
Completed
Trial end date:
2020-07-20
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the vaccines, gp100(g209-2M), and
MAGE-3, when given in combination with resiquimod (R848), can help to stimulate the immune
system against melanoma.